122 related articles for article (PubMed ID: 32910383)
1. Association of Molecular Genetic Markers of TP53, MDM2, and CDKN1A Genes with Progression-Free Survival of Patients with Ovarian Cancer after Platinum-Based Chemotherapy.
Zavarykina TM; Tyulyandina AS; Khokhlova SV; Khabas GN; Asaturova AV; Nosova YA; Brenner PK; Kapralova MA; Atkarskaya MV; Khodyrev DS; Burdennyi AM; Loginov VI; Stenina MB; Sukhikh GT
Bull Exp Biol Med; 2020 Aug; 169(4):486-490. PubMed ID: 32910383
[TBL] [Abstract][Full Text] [Related]
2. TP53 gene status and human papilloma virus infection in response to platinum plus taxane-based chemotherapy of epithelial ovarian carcinomas.
Malisic E; Jankovic R; Jakovljevic K; Radulovic S
J BUON; 2011; 16(4):701-7. PubMed ID: 22331725
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small cell lung cancer.
Zheng D; Chen Y; Gao C; Wei Y; Cao G; Lu N; Hou Y; Jiang X; Wang J
Cancer Biol Ther; 2014; 15(11):1542-51. PubMed ID: 25482940
[TBL] [Abstract][Full Text] [Related]
4. DNA repair gene associated with clinical outcome of epithelial ovarian cancer treated with platinum-based chemotherapy.
Kang S; Sun HY; Zhou RM; Wang N; Hu P; Li Y
Asian Pac J Cancer Prev; 2013; 14(2):941-6. PubMed ID: 23621265
[TBL] [Abstract][Full Text] [Related]
5. TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer.
Santos AM; Sousa H; Portela C; Pereira D; Pinto D; Catarino R; Rodrigues C; Araújo AP; Lopes C; Medeiros R
Biochem Biophys Res Commun; 2006 Feb; 340(1):256-62. PubMed ID: 16364249
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms in
Si W; Kang S; Sun H; Chen J; Cao S; Li Y
Int J Gynecol Cancer; 2019 Sep; 29(7):1148-1155. PubMed ID: 31273068
[TBL] [Abstract][Full Text] [Related]
7. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.
Toffoli G; Biason P; Russo A; De Mattia E; Cecchin E; Hattinger CM; Pasello M; Alberghini M; Ferrari C; Scotlandi K; Picci P; Serra M
Clin Cancer Res; 2009 May; 15(10):3550-6. PubMed ID: 19451596
[TBL] [Abstract][Full Text] [Related]
8. MDM2 T309G has a synergistic effect with P21 ser31arg single nucleotide polymorphisms on the risk of acute myeloid leukemia.
Ebid GT; Sedhom IA; El-Gammal MM; Moneer MM
Asian Pac J Cancer Prev; 2012; 13(9):4315-20. PubMed ID: 23167335
[TBL] [Abstract][Full Text] [Related]
9. Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas.
Galic V; Willner J; Wollan M; Garg R; Garcia R; Goff BA; Gray HJ; Swisher EM
Genes Chromosomes Cancer; 2007 Mar; 46(3):239-47. PubMed ID: 17171684
[TBL] [Abstract][Full Text] [Related]
10. Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival.
Liu L; Wu C; Wang Y; Zhong R; Duan S; Wei S; Lin S; Zhang X; Tan W; Yu D; Nie S; Miao X; Lin D
J Thorac Oncol; 2011 Nov; 6(11):1793-800. PubMed ID: 21841506
[TBL] [Abstract][Full Text] [Related]
11. The association of polymorphic markers Arg399Gln of XRCC1 gene, Arg72Pro of TP53 gene and T309G of MDM2 gene with breast cancer in Kyrgyz females.
Isakova J; Talaibekova E; Aldasheva N; Vinnikov D; Aldashev A
BMC Cancer; 2017 Nov; 17(1):758. PubMed ID: 29132330
[TBL] [Abstract][Full Text] [Related]
12. P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome.
Gadducci A; Di Cristofano C; Zavaglia M; Giusti L; Menicagli M; Cosio S; Naccarato AG; Genazzani AR; Bevilacqua G; Cavazzana AO
Anticancer Res; 2006; 26(1B):687-93. PubMed ID: 16739339
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer.
Zhang X; Miao X; Guo Y; Tan W; Zhou Y; Sun T; Wang Y; Lin D
Hum Mutat; 2006 Jan; 27(1):110-7. PubMed ID: 16287156
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy.
Tecza K; Pamula-Pilat J; Kolosza Z; Radlak N; Grzybowska E
J Exp Clin Cancer Res; 2015 Jan; 34(1):2. PubMed ID: 25591549
[TBL] [Abstract][Full Text] [Related]
15. The Pro allele of the p53 codon 72 polymorphism is associated with decreased intratumoral expression of BAX and p21, and increased breast cancer risk.
Proestling K; Hebar A; Pruckner N; Marton E; Vinatzer U; Schreiber M
PLoS One; 2012; 7(10):e47325. PubMed ID: 23071787
[TBL] [Abstract][Full Text] [Related]
16. TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer.
Zhang GN; Liu H; Huang JM; Wang L; Zhao JS; Li C; Mi K; Zhu Y; Cheng J; Zha X
Gynecol Oncol; 2014 Mar; 132(3):752-7. PubMed ID: 24463159
[TBL] [Abstract][Full Text] [Related]
17. Elevated risk of squamous-cell carcinoma of the lung in heavy smokers carrying the variant alleles of the TP53 Arg72Pro and p21 Ser31Arg polymorphisms.
Popanda O; Edler L; Waas P; Schattenberg T; Butkiewicz D; Muley T; Dienemann H; Risch A; Bartsch H; Schmezer P
Lung Cancer; 2007 Jan; 55(1):25-34. PubMed ID: 17059853
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of LRRC8A protects human ovarian and alveolar carcinoma cells against Cisplatin-induced expression of p53, MDM2, p21Waf1/Cip1, and Caspase-9/-3 activation.
Sørensen BH; Nielsen D; Thorsteinsdottir UA; Hoffmann EK; Lambert IH
Am J Physiol Cell Physiol; 2016 Jun; 310(11):C857-73. PubMed ID: 26984736
[TBL] [Abstract][Full Text] [Related]
19. Association of TP53 and MDM2 polymorphisms with survival in bladder cancer patients treated with chemoradiotherapy.
Shinohara A; Sakano S; Hinoda Y; Nishijima J; Kawai Y; Misumi T; Nagao K; Hara T; Matsuyama H
Cancer Sci; 2009 Dec; 100(12):2376-82. PubMed ID: 19764997
[TBL] [Abstract][Full Text] [Related]
20. TP53 and MDM2 polymorphisms and the risk of endometrial cancer in postmenopausal women.
Zając A; Smolarz B; Stachowiak G; Wilczyński JR
Med Oncol; 2014 Nov; 31(11):286. PubMed ID: 25316267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
